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Abstract 26 
 27 
Chlamydia trachomatis infections have been implicated in problems such as pelvic 28 
inflammatory disease and infertility in females. While there have been some studies 29 
examining the kinetics of ascending infection, there is limited information on the 30 
kinetics of pathology development and cellular infiltrate into the reproductive tissues 31 
in relation to the effects of inoculating dose, and a better understanding of these are 32 
needed if an efficacious vaccine is to be developed. The murine model of female 33 
genital tract Chlamydia muridarum infection is frequently used as a model of human 34 
C. trachomatis reproductive tract infection. To investigate the kinetics of ascending 35 
genital infection and associated pathology development, female BALB/c mice were 36 
intra-vaginally infected with C. muridarum at doses ranging from 5 × 102 to 2.6 × 106 37 
inclusion forming units. We found that the inoculating dose affects the course of 38 
infection and the ascension of bacteria, with the highest dose ascending rapidly to the 39 
oviducts. By comparison, the lowest dose resulted in the greatest bacterial load in the 40 
lower reproductive tract. Interestingly, we found that dose did not significantly affect 41 
the degree of inflammatory cell infiltrate in the various regions. Overall, this data 42 
demonstrates the effects of infectious dose on the kinetics of ascending chlamydial 43 
infection and associated inflammatory infiltration in BALB/c mice. 44 
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Introduction 51 
 52 
Chlamydia trachomatis is the most common sexually transmitted disease worldwide, 53 
causing a large socio-economic burden on health care systems. The World Health 54 
Organisation (WHO) estimates that 92 million new chlamydial infections are detected 55 
each year 1. It is estimated that up to 70% of infections in females and 50% in men are 56 
asymptomatic, causing sequelae such as pelvic inflammatory disease (PID) 2 and 57 
epididymitis 3, respectively. The rise in genital chlamydial infections has coincided 58 
with the rise in not only PID, but also ectopic pregnancy, tubal infertility and 59 
salpingitis 4. The health care cost associated with infections are estimated to be 60 
between $US2-10 billion each year 5, with PID alone estimated to cost $US5.5 billion 61 
annually 6.  62 
 63 
There has been a significant amount of research into development of an efficacious 64 
vaccine in animal models (reviewed in 2, 7). However there is little consistency in the 65 
infectious challenge dose used, with the doses ranging from 1.5 × 103 to 1 × 107 66 
inclusion forming units (ifu) 8, 9. Rank et al. 10 estimated the transmission dose of 67 
Chlamydia caviae in guinea pigs to be 102 ifu, after examining the levels and 68 
progression of infection in female guinea pigs acquired through mating experiments. 69 
The variation in inoculating dose is a problem as it is unclear how the infectious dose 70 
will alter the disease outcomes and the response of the animal. 71 
 72 
There is a basic understanding of the cellular pathogenesis of Chlamydia (reviewed in 73 
11), with limited information about the kinetics of ascending infection and the 74 
associated pathology development. A chlamydial infection induces an influx of 75 
inflammatory cells including neutrophils, T cells, B cells and macrophages that are 76 
stimulated by the production of proinflammatory cytokines and chemokines 11. 77 
Studies show that even low levels of infection, induce a profound immune response 12. 78 
Ex vivo studies using human fallopian tube tissues have indicated that interleukin-1 79 
(IL-1) is the initial proinflammatory cytokine activated by a chlamydial infection and 80 
confirm that this cytokine is involved in tissue destruction 13. Acute and 81 
chronic/persistent infections can promote foci of inflammatory responses along with 82 
promoting tissue remodelling, cellular proliferation and healing that, if persist, lead to 83 
scarring 11. Although there is a role for an adaptive immune response in chlamydial 84 
disease, it is secondary to the secretion of pro-inflammatory cytokines and 85 
chemokines from infected non-immune cells 11. 86 
 87 
However, the exact time-frame of chlamydial ascension along the female reproductive 88 
tract and the level of infection required to induce this response is not known. 89 
Knowledge of the kinetics of infection is essential to aid in the development of a 90 
vaccine, and would demonstrate how the challenge dose affects the final outcomes of 91 
the disease. A study by Maxion et al. 14 has shown that the infectious dose modulates 92 
the innate immune response and that an increased level of infection correlates with a 93 
decrease in oviduct sequelae. In a murine model the effects of infection can vary 94 
depending not only on the inoculating dose and the serovar of Chlamydia 15, but also 95 
on the age of the animal 16, the mouse strain used 17 and the hormone levels present 18.  96 
 97 
As there is limited information on the effects of inoculating dose on the kinetics of C. 98 
muridarum genital infection and its associated pathology development, this study 99 
aimed to examine these in a murine model. 100 
Results 101 
 102 
The infectious dose affects the course of vaginal shedding in mice.  103 
 104 
To monitor the course and degree of infection in the mice, vaginal swabs were 105 
collected every 3 days and were cultured on McCoy cells; the cut-off for a productive 106 
infection was set at 300 ifu. The mid (5 × 104 ifu) and high (2.6 × 106 ifu) dose 107 
infections caused an initial infection 3-fold greater (p<0.001) than the low dose, that 108 
dropped rapidly by day 9 post infection (p.i.) (Fig. 1). The animals that received these 109 
two doses reached the cut off level by day 35 p.i. In contrast, the low dose (5 × 102 110 
ifu) infection group shed significantly greater (p<0.05) levels of Chlamydia 9 days p.i. 111 
On day 35 p.i. this group was still infected, secreting 18-fold more IFU than the mid 112 
and high dose animals, but was not significantly different. By day 42 p.i. the low dose 113 
group reached the cut-off level. 114 
 115 
The infectious dose affects the ascension of Chlamydia in the murine female 116 
reproductive tract.  117 
 118 
While swab collection and analysis allows the level of bacterial shedding in the lower 119 
genital tract to be determined, the removal and culture of tissues allows the level of 120 
viable bacteria present within the submucosal layers of all regions of the genital tract 121 
to be examined. Culture of the cervico-vaginal region revealed that although the 122 
difference between the mid and high inoculating dose is quite large, the level of 123 
infection that occurred in the tissues was not significantly different (Fig. 2A). In both 124 
groups, infection was not detected in the cervico-vaginal tissues from day 21 p.i. 125 
However, the low dose group had a significantly higher initial infection (day 6 p.i.) in 126 
this region than the mid (p<0.01) and high dose (p<0.05) groups.  127 
  128 
In the uterine horn tissues (Fig. 2B) the low dose group had a similar course of 129 
infection as the mid and high doses, with the exception of a peak in infection at day 9 130 
(p<0.001), which was not observed with the other doses. The chlamydial burden 131 
within the uterine horns for all 3 doses was much lower than that observed in the 132 
cervico-vaginal region and oviducts. 133 
 134 
The oviduct tissues had the greatest chlamydial burden of any of the regions. The high 135 
dose had a 7.5 – 13 fold greater infection (p<0.001) than the mid and low doses, 136 
respectively, on day 6 p.i. (Fig. 2C). The mid and low dose groups had a similar 137 
degree of infection. From day 9 p.i. all three groups had the same pattern of infection. 138 
Interestingly, the chlamydial burden within the oviducts was higher than that seen in 139 
the uterine horn and cervico-vaginal tissues for all 3 doses during the early stages of 140 
infection. 141 
 142 
Overall, the infectious dose affects the degree of ascending infection in the murine 143 
FRT, with rapid ascension to the oviducts observed in mice that received the high 144 
dose, despite the low dose causing greater infections in the lower regions of the 145 
reproductive tract. 146 
 147 
The infectious dose affects the development of pyosalpinx but not hydrosalpinx.  148 
 149 
Pyosalpinx is defined as the oviduct containing pus and is often a result of acute 150 
salpingitis. Hydrosalpinx is defined as dilation of the oviducts and luminal filling with 151 
a clear serous fluid and is used as an indicator of infertility 19. The animals that 152 
received the low dose did not appear to develop gross visual pathology as severe as 153 
the two higher doses by 42 days p.i., despite similar infection levels (Fig. 3A). This 154 
group was therefore extended, with animals examined at days 49 and 70 p.i, and 155 
showed that hydrosalpinx developed to the same degree as seen with the 2 higher 156 
doses, but at later time-points. The low dose group had very low levels of pyosalpinx 157 
until day 15 p.i.  In contrast, the mice that received the mid dose of infection 158 
developed pyosalpinx by day 6 p.i., with it being most severe at 9 days p.i. (Fig 3B). 159 
By day 35 p.i. hydrosalpinx was present and quite severe and continued to day 42 p.i., 160 
when the experiment was terminated. Similarly, the mice that received the high dose 161 
of infection also developed pyosalpinx, but the severity peaked at day 12 p.i. By day 162 
35 p.i., hydrosalpinx had developed in these mice (Fig. 3C).  163 
 164 
Overall it was found that the low dose group had the least severe pyosalpinx 165 
development and all 3 groups developed very similar degrees of hydrosalpinx, albeit 166 
the low dose group was at a later time-point. 167 
 168 
The infectious dose does not significantly alter the level of inflammatory cell 169 
infiltration throughout the course of infection.  170 
 171 
The histopathological changes in the 3 regions of the reproductive tracts were 172 
measured using H&E stain and the levels of acute (neutrophils) and chronic 173 
(lymphocytes) inflammation were measured. 174 
 175 
Acute Inflammation: 176 
An increased presence of neutrophils is indicative of an acute infection at the site and 177 
they are important in this model as they are required for the clearance of chlamydial 178 
infections 20. The greatest levels of infiltrate were seen during the acute phase of 179 
infection in all 3 groups in all the regions (Fig. 4). Surprisingly, within the cervico-180 
vaginal region there was no significant difference in the level of neutrophils observed 181 
between any of the groups or in comparison to the control (Fig. 4A). In the uterine 182 
horn tissues all 3 groups had significantly greater levels of neutrophil infiltrate than 183 
the controls on day 6 p.i. (p<0.001, p<0.05, p<0.01 respectively), but dropped to very 184 
low levels by day 15 p.i. in all 3 groups (Fig. 4B). On day 9 p.i. the low dose group 185 
had significantly greater infiltrate than the mid and high dose (p<0.05 and p<0.001 186 
respectively), correlating with the greater chlamydial burden seen in the uterine 187 
tissues at this time-point. Interestingly, the numbers of neutrophils present in the 188 
uterine horn tissues during the very early stages of infection were much greater than 189 
that seen in the cervico-vaginal regions. In the oviducts the level of neutrophils was 190 
greatest on days 9-15 p.i., after which, they dropped, coinciding with the clearance of 191 
Chlamydia from the oviduct tissues (Fig. 4C). Neutrophil presence in the mid and 192 
high dose, at these time-points correlates with the presence, of pyosalpinx (Fig. 3). 193 
 194 
Chronic Inflammation: 195 
The presence of lymphocytes within the tissues can represent chronic inflammation 196 
and in these experiments all 3 regions of the reproductive tract had elevated levels of 197 
lymphocyte infiltration compared to the negative and progesterone controls (Fig. 5). 198 
Specifically, in the mice that received the mid dose, the levels of infiltrate in the 199 
cervico-vaginal region were significantly greater than controls on days 9 and 12 p.i. 200 
(p<0.01 and p<0.05 respectively; Fig. 5A). Within the uterine horn tissues both the 201 
low and mid dose groups demonstrated a trend of increased levels of lymphocyte 202 
infiltration compared to both control groups at numerous time-points (Fig. 5B)., but 203 
overall, it was the mid dose that induced the greatest lymphocyte infiltrate present at 204 
all time-points until day 35 p.i. In the oviducts (Fig. 5C) the overall level of infiltrate 205 
was much lower than that observed in the cervix/vagina and uterine horns. All 206 
lymphocyte infiltrate in the oviduct had subsided by day 35 p.i., the time at which 207 
hydrosalpinx was observed. There was an overall trend, with the mid dose having the 208 
greatest levels of lymphocytic infiltrate in all 3 regions of the reproductive tract 209 
during the acute stages of infection (days 6 – 21 p.i.). 210 
 211 
The levels of neutrophils were only elevated for a short period of time that coincided 212 
with the peak infection levels within the tissues. In contrast, even after the infection 213 
had cleared from the tissues, the level of lymphocyte infiltration remained elevated. 214 
Overall, the level of inflammatory cell infiltrate was not significantly affected by the 215 
levels of infection seen in the 3 regions of the reproductive tract 216 
 217 
 218 
 219 
 220 
 221 
 222 
 223 
 224 
Discussion 225 
 226 
In this study we have demonstrated the kinetics of ascending genital tract chlamydial 227 
infection and the associated inflammation kinetics in female BALB/c mice. We have 228 
shown that the infectious dose of C. muridarum alters both the rate and level of 229 
clearance and ascension in the female reproductive tract and the development of gross 230 
pathology. However the overall level of inflammatory cell infiltrate was not 231 
significantly affected by the infectious dose administered, highlighting that inoculum 232 
that is 5000 fold less than the highest used here is sufficient to cause inflammatory 233 
infiltrate to a similar, if not greater degree.  234 
 235 
The pattern of chlamydial shedding from the cervico-vaginal region was similar to 236 
that reported previously 14, 21. Interestingly, there were only two time-points where the 237 
levels of shed bacteria significantly differed to each other. However, examination of 238 
the chlamydial burden within the tissues of the 3 regions of the mouse FRT 239 
highlighted differences between the groups, with the low dose able to ascend to infect 240 
the uterine horns to a greater degree than the mid and high dose. In contrast, it was the 241 
high dose that ascended to the oviducts to the greatest degree. This difference within 242 
the oviducts may have been because the lower reproductive tract was overloaded with 243 
Chlamydia and canalicular spread has allowed Chlamydia that were not bound to 244 
epithelial cells to migrate to areas where there were uninfected cells, including the 245 
oviducts. This overloading of epithelium with Chlamydia has previously been 246 
suggested by Kelly et al. 22.  247 
 248 
The infectious dose modulates the innate immune response in relation to the infection 249 
14, with the level of chlamydial burden being directly related to the development of 250 
oviduct pathology. Maxion 14 reported that there were differences in oviduct dilation 251 
and trends in the ability of increasing doses to cause a greater infiltration of both 252 
adaptive and innate immune cells such as polymorphonuclear cells (PMN) 14. This 253 
was not seen in our study, with the high dose causing the greatest infection in the 254 
oviducts and no significant differences in the levels of infiltrating cells. This may be 255 
linked to different variants of C. muridarum being used. There are 2 naturally 256 
occurring isolates of C. muridarum, Weiss and Nigg II. Recently it has been found 257 
that while these two variants are identical in their patterns of infection, they differ in 258 
their virulence 23. Maxion et al. 14 do not state which strain of C. muridarum has been 259 
used, but based on their obtained ID50 (2.5 × 103 ifu) and all of the animals in this 260 
study becoming infected at 5 × 102 ifu, using the same strain of mice, this suggests 261 
that different variants may have been used by Maxion et al. 14 and our group and 262 
therefore could explain the differences found. 263 
 264 
 The chlamydial burden seen in the uterine horns was much lower than that observed 265 
in the oviducts. Recruitment of CD45+ major histocompatibility complex class II 266 
(MHC II) cells limit the level of infection in uterine tissues early in infection 24, 267 
suggesting that an early MHC class II response may have limited the level of infection 268 
within the uterine tissues in this case. The cervico-vaginal regions had a greater 269 
overall chlamydial burden than the uterine and oviduct tissues and a more prolonged 270 
infection. This may be because the immune system in that region of the reproductive 271 
tract may be dampened due its continual contact with natural flora and other potential 272 
pathogens, allowing the bacteria to initially infect epithelial cells to a greater degree 273 
22.  274 
 275 
We have also demonstrated that the development of gross pathology is not necessarily 276 
dose dependent, with the low dose developing a similar level of hydrosalpinx as the 277 
mid and high dose groups but at a later time-point. Pyosalpinx is defined as the 278 
presence of PMN’s, or pus, within the oviduct, and in these experiments was found to 279 
occur during the acute infection stages. Hydrosalpinx occurs when the oviducts are 280 
occluded and clear serous fluid accumulates causing oviduct dilation 19. Many 19, 25 281 
have used the presence of hydrosalpinx as a marker for infertility in the mouse model, 282 
with Shah et al. 19 demonstrating that oviduct occlusion directly correlates to 283 
infertility in mice. The presence of hydrosalpingeal fluid in women undergoing in 284 
vitro fertilisation has been linked to decreased implantation rates 26. The exact reasons 285 
behind this are unclear, but it is believed that the fluid contains cytokines such as IL-286 
2, that are involved in the development of pathology, and it is this pathology 287 
development that decreases the rate of successful pregnancy outcomes 26. Here we 288 
found that the mid dose had the greatest overall level of hydrosalpinx development, 289 
possibly related to greater levels of chronic pathology (lymphocytes) and also a more 290 
prolonged presence of neutrophils. Whilst the development of pyosalpinx and 291 
hydrosalpinx have been examined in both C57BL/6 and C3H/HeN mice 19, this is the 292 
first time, to our knowledge, that the kinetics of their development has been examined 293 
in the BALB/c model, at multiple time-points and at varying infectious doses.  294 
 295 
Importantly, we have demonstrated that the infectious dose administered did not 296 
significantly affect the overall level of inflammatory cell infiltration. We have shown 297 
that neutrophils are present in the early stages of infection in all three regions of the 298 
mouse reproductive tract. Treatment of animals with granulocyte-depleting 299 
monoclonal antibodies has shown that neutrophils play a critical role in the clearance 300 
of early stage chlamydial infections from the reproductive tract 20, but too intense a 301 
neutrophil response may promote pathology development 27. Here we have seen that 302 
the mid dose had a more prolonged elevation of neutrophil infiltration in the oviducts 303 
and the greatest level of hydrosalpinx development at the earlier timepoints. It is 304 
believed that the actual chlamydial infection is not the cause of the inflammation or 305 
pathology development, but rather the host immune response 12. This is supported by 306 
findings from fallopian tube samples of hysterectomy patients, where infection levels 307 
were disproportional to the severity of tissue destruction 13. Upon infection an 308 
epithelial cell secretes various pro-inflammatory cytokines and it is believed that this 309 
cytokine secretion triggers a cascade of events that leads to the development of 310 
chronic pathology, scarring and tubal infertility 11, 28. 311 
 312 
With the transmission rates of C. trachomatis on the rise, 50-60% of infections being 313 
asymptomatic and potential sequelae such as PID, there is a need to understand the 314 
mechanisms of ascending infection leading to pathology development and to develop 315 
ways of preventing the damage. This work highlights that a low level inoculum can 316 
cause a similar level of damage as one more than 5000 times greater, suggesting that 317 
using a high inoculum to establish infection is unnecessary and in fact may result in 318 
an under estimation of the effectiveness of experimental vaccines. Importantly, we 319 
have demonstrated the kinetics of not only ascending genital tract infection in mice, 320 
but also the development of infection related inflammation and pathology in relation 321 
to varying infectious doses.  322 
Materials and Methods 323 
 324 
Chlamydia Strain 325 
 326 
Chlamydia muridarum (Weiss; ATCC VR-123, Virginia, USA), formerly the mouse 327 
pneumonitis biovar of C. trachomatis (MoPn), was grown by inoculation of McCoy 328 
cell monolayers in Dulbecco’s minimal essential medium supplemented with 5% fetal 329 
calf serum (FCS), 2mM L-glutamine, 100µg/mL Streptomycin sulfate, 2µg/mL 330 
Gentamycin and 20mM HEPES. Elementary bodies were purified using a 331 
discontinuous Renografin gradient as previously described 29. 332 
 333 
Mice 334 
 335 
Female BALB/c mice, 6-8 weeks of age, were obtained from The Animal Resource 336 
Centre, Perth (Australia), and housed in an accredited laboratory animal care facility 337 
under specific-pathogen free conditions. Animals received food and water ad libitum. 338 
All procedures were approved by the Queensland University of Technology Animal 339 
Research Ethics Committee. 340 
 341 
Infection  342 
 343 
Mice were given 2.5mg of medroxyprogesterone acetate (Depo-Provera, Pfizer, NSW, 344 
Australia) subcutaneously, seven days prior to infection. The mice were anaesthetised 345 
intraperitoneally using ketamine (Parnell Laboratory, NSW, Australia) and xylazine 346 
hydrochloride (Bayer, NSW, Australia) and infected intra-vaginally with 20µl of 347 
sucrose-phosphate-glutamate (SPG) containing one of the 3 infectious doses, 5 × 102 348 
inclusion forming units (ifu; low), 5 × 104 ifu (mid) or 2.6 × 106 ifu (high). Mice were 349 
then sacrificed on days 6, 9, 12, 15, 21, 35 and 42 post-infection. The low dose group 350 
also had animals sacrificed on days 49 and 70 post infection to examine the extended 351 
pathology development. 352 
 353 
Detection of C. muridarum Infection 354 
 355 
Infection was monitored by collecting cervico-vaginal swabs (Copan, CA, USA) on 356 
the days mentioned above. Swabs were placed in tubes containing 500μl SPG and 357 
glass beads and were stored at -80°C. To monitor the infection individual wells of 358 
McCoy cell monolayers in 48 well plates were inoculated with 10μl of swab specimen 359 
and media. Plates were incubated for 4 hours at 37°C, after which the swab solution 360 
was removed and replaced with fresh supplemented media containing 1μg/mL 361 
cycloheximide. The wells were incubated for a further 24-30 hours, then fixed with 362 
methanol. The inclusions were visualised by staining with rabbit anti-C. trachomatis 363 
antibody (Pierce/Progen, Richlands, Australia) and Immunopure ABC/DAB Staining 364 
Kit (Pierce/Progen, Richlands, Australia), as described elsewhere 21. An animal was 365 
classed as having a productive infection if there were greater than 300 ifu’s per swab. 366 
 367 
Assessment of Ascending Infection 368 
 369 
To monitor the progress of the infection along the reproductive tract the cervico-370 
vaginal region, uterine horns and oviducts representing the upper reproductive tract, 371 
were removed upon sacrifice, placed in 100μl SPG and stored at -80ºC. To determine 372 
the chlamydial burden within the tissues, individual cervico-vaginal, uterine horns and 373 
pooled oviducts were weighed and homogenised, and 10-25μl of homogenate was 374 
placed onto individual wells of McCoy cell monolayers and cultured and stained as 375 
above. Inclusions present in 20 fields (× 40 magnification) were counted and the ifu/1 376 
mg of tissue was calculated. 377 
 378 
Assessment of Gross Pathology  379 
 380 
Upon sacrifice the reproductive tracts were examined in situ for macroscopic changes. 381 
The presence of pyosalpinx and hydrosalpinx was recorded and the level of fluid 382 
retention was also scored, with those having small amounts of fluid present in the 383 
oviducts given a score of 1, those with moderate amounts a score of 2 and those with 384 
large amounts of fluid given a score of 3.  385 
 386 
Histopathology Assessment 387 
 388 
Tissues were removed at sacrifice, fixed in 10% formaldehyde and embedded in 389 
paraffin wax. Five µm sections were cut, dewaxed and rehydrated through graded 390 
ethanol solutions to PBS. Haematoxylin and eosin staining was performed. Regions of 391 
the reproductive tract, cervix/vagina, uterine horn and oviducts, were counted 392 
separately to each other. Ten random fields (× 1000 magnification) of each were 393 
counted ensuring to include both epithelium and sub-mucosa, with the observer 394 
blinded to the time-point and dose being examined. 395 
 396 
Statistics 397 
 398 
All data are presented as mean ± standard error of mean (SE). All statistics were 399 
performed using GraphPad Prism version 5.00 (GraphPad Software, CA, USA). 400 
Significant differences in the swab clearance data, tissue ifu and inflammatory cell 401 
infiltration was determined using a two-way ANOVA with Bonferroni’s post test with 402 
significance set for p<0.05. All experiments contained 5 mice and were repeated 403 
twice. 404 
 405 
 406 
 407 
 408 
 409 
 410 
 411 
 412 
 413 
 414 
 415 
 416 
 417 
 418 
 419 
 420 
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 544 
Figure Legends 545 
 546 
 Figure 1: Course of infection determined by vaginal swabs after vaginal inoculation 547 
with varying doses of C. muridarum. Vaginal swabs were collected days 6, 9, 12, 15, 548 
21 and 35 post vaginal infection to determine levels of viable organisms by McCoy 549 
cell culture. Data are mean ± SE of mean for 10 mice, from two separate experiments, 550 
with a productive infection classified as greater than 300 ifu. Two-way ANOVA was 551 
performed with Bonferroni’s post test. †: p<0.05 (low compared to high dose); #: 552 
p<0.001 (low compared to mid dose). 553 
 554 
Figure 2: Kinetics of infection in (A) cervico-vaginal, (B) uterine horn and (C) 555 
oviduct tissue homogenate culture after vaginal inoculation with varying doses of C. 556 
muridarum. Tissues collected at various time-points were homogenised, equal 557 
amounts cultured on McCoy cell monolayers and ifu/1 mg of tissue was determined. 558 
Data are mean ± SE for 10 mice. Two-way ANOVA with Bonferroni’s post test was 559 
performed. †: p<0.05; *: p<0.01; #: p<0.001. 560 
 561 
Figure 3: Course of gross pathology development, including pyosalpinx and 562 
hydrosalpinx, over the time-points examined. (A) Low dose; (B) Mid dose; (C) High 563 
dose. Visual observations were made at the time of sacrifice. Scoring system was: 1: 564 
low level of fluid present in oviduct; 2: moderate amount of fluid present; and 3: large 565 
level of fluid present. The data represents two separate experiments, each containing 5 566 
mice, and is the mean ± SE of values obtained. ND: Not determined at these 567 
timepoints. 568 
 569 
Figure 4: The kinetics of neutrophil (acute) infiltration within the (A) cervix/vagina; 570 
(B) uterine horn; (C) oviduct of the murine female reproductive tract. Data are mean ± 571 
SE for 10 mice. Two-way ANOVA was performed with Bonferroni’s post test. N: 572 
Negative animals, P: Progesterone treated only animals. †: p<0.05; *: p<0.01; #: 573 
p<0.001. 574 
 575 
Figure 5: The kinetics of lymphocyte (chronic) infiltration within the (A) 576 
cervix/vagina; (B) uterine horn; (C) oviducts of the murine female reproductive tract. 577 
Data are mean ± SE for 10 mice. Two-way ANOVA was performed with 578 
Bonferroni’s post test. N: Negative animals, P: Progesterone treated only animals. †: 579 
p<0.05; *: p<0.01; #. 580 
 581 
